Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Restructuring and other charges
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — restructuring and other charges?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — restructuring and other charges of $0 in Q2 2026.
- What does avkare — restructuring and other charges mean?
- Captures costs associated with organizational realignment, facility closures, or significant changes in the AvKARE segment's business structure intended to improve long-term profitability. These charges are typically excluded from core operating metrics to provide a clearer view of ongoing business performance.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — restructuring and other charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude